XML 41 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Mar. 10, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Registrant Name Sana Biotechnology, Inc.    
Entity Central Index Key 0001770121    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Current Fiscal Year End Date --12-31    
Entity Filer Category Accelerated Filer    
Entity Common Stock, Shares Outstanding   225,024,899  
Entity Public Float     $ 595.6
Entity Shell Company false    
Entity Small Business false    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
Entity File Number 001-39941    
Entity Tax Identification Number 83-1381173    
Entity Address Address Line1 188 East Blaine Street    
Entity Address, Address Line Two Suite 400    
Entity Address City Or Town Seattle    
Entity Address State Or Province WA    
Entity Address Postal Zip Code 98102    
City Area Code 206    
Local Phone Number 701-7914    
Document Annual Report true    
Document Transition Report false    
Entity Incorporation State Country Code DE    
Title of 12(b) Security Common Stock, $0.0001 par value per share    
Trading Symbol SANA    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction false    
Auditor Name Ernst & Young LLP    
Auditor Location Seattle, Washington    
Auditor Firm ID 42    
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant’s definitive Proxy Statement relating to its 2025 Annual Meeting of Stockholders (Proxy Statement) are incorporated by reference into Part III of this Annual Report on Form 10-K (Annual Report) where indicated. The Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Annual Report relates.

    
Auditor Opinion

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Sana Biotechnology, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive loss, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.